Around five months after its long-serving chief executive Doug Ingram announced he was stepping down, Sarepta Therapeutics ...

Scribe Therapeutics has become the latest biotech to list on the Nasdaq in the US, raising more than $155 million to advance ...

After three knockbacks by the FDA, Outlook Therapeutics has finally pushed its therapy for wet age-related macular ...

In a major shake-up of its UK operations, GSK has started building a brand new R&D centre in Cambridge and will transfer operations there from its current site in Stevenage, Hertfordshire, which has ...

Johnson & Johnson has made a $5.5 billion bid to finally bring more than 15 years of litigation over the safety of its talcum powder products to a close. The settlement offer is dependent on 95% of ...

In a special report (PDF) published to mark the International AIDS Conference underway in Rio de Janeiro, Brazil, the UNAIDS organisation has warned that efforts to end HIV as a public health threat ...

MSD is paying $20 million upfront to activate an alliance with Flagship Pioneering's Quotient Therapeutics that will focus on finding new therapeutic targets in inflammatory bowel disease (IBD). The ...

Chris McDonald has been named the next UK Minister for Science, following the resignation of Patrick Vallance last week, at ...

Johnson & Johnson's oral IL-23 inhibitor Icotyde, tipped to become a future blockbuster, has been recommended as a frontline ...

Netherlands- and Belgium-based biotech argenx has agreed to buy US biotech Forte Biosciences for up to $2.2 billion, ...

Biotech companies looking to commercialise their innovations in Europe must make the business-critical choice of whether to ...

While a relatively minor setback for Ultomiris – which grew 14% to nearly $2.6 billion in the first half – the result is a ...